Liver-specific overexpression of lipoprotein lipase improves glucose metabolism in high-fat diet-fed mice.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
01
2022
accepted:
25
08
2022
entrez:
13
9
2022
pubmed:
14
9
2022
medline:
16
9
2022
Statut:
epublish
Résumé
The liver is the main organ that regulates lipid and glucose metabolism. Ectopic lipid accumulation in the liver impairs insulin sensitivity and glucose metabolism. Lipoprotein lipase (LPL), mainly expressed in the adipose tissue and muscle, is a key enzyme that regulates lipid metabolism via the hydrolysis of triglyceride in chylomicrons and very-low-density lipoproteins. Here, we aimed to investigate whether the suppression level of hepatic lipid accumulation via overexpression of LPL in mouse liver leads to improved metabolism. To overexpress LPL in the liver, we generated an LPL-expressing adenovirus (Ad) vector using an improved Ad vector that exhibited considerably lower hepatotoxicity (Ad-LPL). C57BL/6 mice were treated with Ad vectors and simultaneously fed a high-fat diet (HFD). Lipid droplet formation in the liver decreased in Ad-LPL-treated mice relative to that in control Ad vector-treated mice. Glucose tolerance and insulin resistance were remarkably improved in Ad-LPL-treated mice compared to those in control Ad vector-treated mice. The expression levels of fatty acid oxidation-related genes, such as peroxisome proliferator-activated receptor α, carnitine palmitoyltransferase 1, and acyl-CoA oxidase 1, were 1.7-2.0-fold higher in Ad-LPL-treated mouse livers than that in control Ad-vector-treated mouse livers. Furthermore, hepatic LPL overexpression partly maintained mitochondrial content in HFD-fed mice. These results indicate that LPL overexpression in the livers of HFD-fed mice attenuates the accumulation of lipid droplets in the liver and improves glucose metabolism. These findings may enable the development of new drugs to treat metabolic syndromes such as type 2 diabetes mellitus and non-alcoholic fatty liver disease.
Identifiants
pubmed: 36099304
doi: 10.1371/journal.pone.0274297
pii: PONE-D-22-00118
pmc: PMC9469954
doi:
Substances chimiques
Triglycerides
0
Lipoprotein Lipase
EC 3.1.1.34
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0274297Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Diabetes. 2002 Oct;51(10):2944-50
pubmed: 12351431
Endocr J. 2012;59(10):849-57
pubmed: 22878669
J Lipid Res. 1989 Mar;30(3):423-31
pubmed: 2723548
Immunity. 1994 Aug;1(5):433-42
pubmed: 7533647
J Clin Invest. 2004 Jul;114(2):147-52
pubmed: 15254578
Exp Clin Endocrinol Diabetes. 2022 Apr;130(4):254-261
pubmed: 33782927
Hum Gene Ther. 1998 Nov 20;9(17):2577-83
pubmed: 9853524
Hepatol Commun. 2019 Jun 06;3(8):1098-1112
pubmed: 31388630
Mol Cell Proteomics. 2018 Dec;17(12):2371-2386
pubmed: 30171159
Lancet. 2010 Jun 26;375(9733):2267-77
pubmed: 20609972
N Engl J Med. 2014 Dec 4;371(23):2237-8
pubmed: 25470706
Arch Biochem Biophys. 1996 Feb 15;326(2):281-9
pubmed: 8611035
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2532-9
pubmed: 9409224
Circ Res. 2008 Feb 29;102(4):401-14
pubmed: 18309108
J Lipid Res. 1996 Apr;37(4):693-707
pubmed: 8732771
Diabetes Obes Metab. 2010 Oct;12 Suppl 2:83-92
pubmed: 21029304
Eur J Biochem. 1997 Feb 15;244(1):1-14
pubmed: 9063439
J Physiol. 2012 Jul 15;590(14):3349-60
pubmed: 22586215
Cell Mol Life Sci. 2004 Feb;61(4):393-416
pubmed: 14999402
Mol Ther Methods Clin Dev. 2014 Sep 03;1:14035
pubmed: 26015975
Hepatology. 2010 Feb;51(2):679-89
pubmed: 20041406
J Virol. 1996 Dec;70(12):8944-60
pubmed: 8971024
Am J Physiol. 1990 Apr;258(4 Pt 1):C673-81
pubmed: 2185641
Nature. 2014 Jun 5;510(7503):84-91
pubmed: 24899308
Biochem Biophys Rep. 2017 Apr 20;10:192-197
pubmed: 28955747
Virology. 1968 Sep;36(1):115-25
pubmed: 5669982
J Clin Endocrinol Metab. 2007 Apr;92(4):1467-73
pubmed: 17244782
Endocr Connect. 2015 Mar;4(1):R1-R15
pubmed: 25385852
Nat Genet. 1992 Aug;1(5):372-8
pubmed: 1302034
J Clin Invest. 2011 Jun;121(6):2094-101
pubmed: 21633177
J Endocrinol. 2014 Jan 15;220(2):T61-79
pubmed: 24323910
FASEB J. 2019 Dec;33(12):13310-13322
pubmed: 31530015
J Lipid Res. 2016 Jul;57(7):1155-61
pubmed: 27234787
Cell Metab. 2011 Nov 2;14(5):569-70
pubmed: 22055498
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2730-5
pubmed: 12606719
Metabolism. 2021 Dec;125:154892
pubmed: 34563556
Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E271-88
pubmed: 19318514
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7522-7
pubmed: 11390966
Nat Med. 2017 Jul 11;23(7):804-814
pubmed: 28697184
J Biol Chem. 2001 Oct 26;276(43):40071-9
pubmed: 11477088
Hum Gene Ther. 1999 Aug 10;10(12):2013-7
pubmed: 10466635
Cell. 2012 Mar 2;148(5):852-71
pubmed: 22385956
Circulation. 2011 Dec 13;124(24):e837-41
pubmed: 22156000
Am J Physiol Endocrinol Metab. 2000 Nov;279(5):E1039-44
pubmed: 11052958
Cell Metab. 2005 May;1(5):309-22
pubmed: 16054078
J Immunol. 2021 Jan 15;206(2):410-421
pubmed: 33277385